- Acute and subacute infections of the upper and lower respiratory tract: bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis media, including complications after influenza (treatment as part of combination therapy).
- Recurrent infections of the upper and lower respiratory tract, chronic bronchitis (prevention of exacerbations).
Combined immunostimulating drug of bacterial origin for sublingual (sublingual) administration.
It is a polyvalent antigenic complex, including lysates of bacteria - the most common pathogens of respiratory infections.
The lysates that are part of Ismigen are obtained by mechanical action.
Ismigen, like other immunostimulants of bacterial origin of the second generation, has a non-specific immunostimulating and specific vaccinating effect.
Ismigen sublingual tablets has an effect on various parts of the immune system.
Stimulates both local cellular and humoral immune response and systemic immune response.
Activates phagocytosis, increases the content of lysozyme in saliva, increases the number of immunocompetent cells.
Increases the functional and metabolic activity of macrophages (including alveolar) and polymorphonuclear leukocytes.
It activates the processes of peroxidation and the expression of adhesion molecules on macrophage-monocytic cells and granulocytes LEA-1, MAC-1, p-150, ICAT-1, which ensures cooperation with T-lymphocytes and antigen-presenting cells and contributes to the destruction of infectious agents.
Stimulates the secretion of prostaglandin E2 by macrophage-monocytic cells, activates natural killers; stimulates the release of anti-inflammatory cytokines - interleukin (IL)-1, IL-2, IL-6, IL-8, interferon gamma, tumor necrosis factor alpha; inhibits the synthesis of IL-4, IL-12; increases the concentration of secretory immunoglobulin (Ig) A in saliva, serum IgA, IgG, IgM; reduces the concentration of serum IgE.
As a result of treatment with Ismigen, the frequency, severity and duration of acute infections of the respiratory tract are reduced; there is relief and leveling of such symptoms as fever, cough, shortness of breath, the need for antibacterial and anti-inflammatory therapy decreases; in patients with chronic diseases of the respiratory tract, the drug also prevents exacerbations.
Composition per tablet: Lyophilized bacterial lysates - 50 mg, including the active ingredient: bacterial lysates of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae (types - TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ 24), Klebsiella pneumoniae, Klebsiella ozaenae, Haemophilus influenzae b, Neisseria catarrhalis - 7.0 mg; excipient: glycine - 43 mg. Excipients - microcrystalline cellulose 150.0 mg, calcium hydrophosphate dihydrate 35.0 mg, colloidal silicon dioxide 10.0 mg, magnesium stearate 3.0 mg, ammonium glycyrrhizinate 1.2 mg, mint flavor 0.8 mg.
Under the tongue; take on an empty stomach. The tablet should be kept under the tongue until completely dissolved. Sublingual tablets should not be sucked, chewed or swallowed.
Acute and subacute infections of the upper and lower respiratory tract - 1 tablet per day until the symptoms of the disease disappear (at least 10 days).
Recurrent infections of the upper and lower respiratory tract, prevention of exacerbations of chronic respiratory diseases - 1 tablet per day for 10 days.
The prophylactic course includes three cycles of 10 days with 20-day intervals between them. A preventive course should be carried out no more than 1-2 times a year.
If you miss taking the next dose, do not double it at the next dose.
